Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Dyne Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 - WALTHAM, Mass., August 3, 2023 – Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the second quarter of 2023 and business highlights. “This is an exciting time for the entire Dyne team as we continue to enroll and dose patients in our ACHIEVE and DELIVER trials and are on track to report our first clinical data from both during the second half of this year, including evalua..."
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/15/2023 144 Form 144 - Report of proposed sale of securities:
06/15/2023 4 Scalzo Richard William (See Remarks) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Sold 1,390 shares @ $12.43, valued at $17.3k
Sold 40,000 shares @ $12.89, valued at $515.6k
Sold 10,000 shares @ $12.03, valued at $120.3k
Exercised 40,000 options to buy @ $1.03, valued at $41.2k
06/12/2023 144 Form 144 - Report of proposed sale of securities:
06/12/2023 4 Brumm Joshua T (See Remarks) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Gifted 20,000 shares @ $0
Gifted 1,800 shares @ $0
Sold 46,811 shares @ $13.15, valued at $615.6k
Sold 14,189 shares @ $13.47, valued at $191.1k
Sold 76,582 shares @ $13.34, valued at $1M
Sold 187,748 shares @ $12.61, valued at $2.4M
Exercised 30,088 options to buy @ $1.03, valued at $31k
Exercised 76,582 options to buy @ $1.03, valued at $78.9k
Exercised 171,360 options to buy @ $1.03, valued at $176.5k
06/09/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 144 Form 144 - Report of proposed sale of securities:
05/25/2023 4 Stehman-Breen Catherine (Director) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Granted 24,900 options to buy @ $13.49, valued at $335.9k
05/25/2023 4 Rhodes Jason P (Director) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Granted 24,900 options to buy @ $13.49, valued at $335.9k
05/25/2023 4 Lubner David Charles (Director) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Granted 24,900 options to buy @ $13.49, valued at $335.9k
05/25/2023 4 Kersten Dirk (10% Owner) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Granted 24,900 options to buy @ $13.49, valued at $335.9k
05/25/2023 4 Incerti Carlo (Director) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Granted 24,900 options to buy @ $13.49, valued at $335.9k
05/25/2023 4 HURWITZ EDWARD (Director) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Granted 24,900 options to buy @ $13.49, valued at $335.9k
05/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2023 8-K Quarterly results
Docs: "Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights - On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 - WALTHAM, Mass., May 11, 2023 – Dyne Therapeutics, Inc. , a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2023 and business highlights. “We are making excellent progress in both our ACHIEVE and DELIVER trials and are on track to report initial data from both in the second half of 2023, including evaluating the key disease-driving biomarkers of splicing in DM1 and dystrophin in DM..."
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
03/15/2023 4 Scalzo Richard William (See Remarks) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Sold 1,311 shares @ $13.33, valued at $17.5k
03/15/2023 4 McNeill Jonathan (See Remarks) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Sold 1,000 shares @ $13, valued at $13k
Sold 1,209 shares @ $13.33, valued at $16.1k
03/15/2023 4 HIGH SUSANNA GATTI (COO) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Sold 1,559 shares @ $13.33, valued at $20.8k
03/15/2023 4 Farwell Wildon (Chief Medical Officer) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Sold 7,441 shares @ $13.33, valued at $99.2k
03/15/2023 4 Brumm Joshua T (See Remarks) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Sold 7,318 shares @ $13.33, valued at $97.5k
03/15/2023 4 Beskrovnaya Oxana (Chief Scientific Officer) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Sold 1,416 shares @ $13.33, valued at $18.9k
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Quarterly results
Docs: "Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights - Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD -"
03/02/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/02/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/09/2023 SC 13G/A MPM BIOVENTURES 2018, L.P. reports a 9.5% stake in Dyne Therapeutics, Inc.
02/09/2023 SC 13G BlackRock Inc. reports a 4.9% stake in DYNE THERAPEUTICS INC
02/08/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/23/2023 4 McNeill Jonathan (See Remarks) has filed a Form 4 on Dyne Therapeutics, Inc.
Txns: Sold 10,000 shares @ $14.03, valued at $140.3k
Exercised 10,000 options to buy @ $0.73, valued at $7.3k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy